 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 查看: 2486 | 回復(fù): 12 | |||
Tina_1988銅蟲 (初入文壇)
|
[求助]
求助來(lái)那替尼上市信息？ 已有1人參與
|
||
| 在網(wǎng)上看到有公司掛來(lái)那替尼項(xiàng)目合作信息，在CDE上有來(lái)那替尼片的進(jìn)口申請(qǐng)，但是我卻查不到該藥的具體上市信息，特此求助，望大俠相幫，謝謝！ |
回復(fù)此樓» 收錄本帖的淘帖專輯推薦
 顓頊藥學(xué) |
» 猜你喜歡
各國(guó)和國(guó)際組織現(xiàn)行藥典注射用水質(zhì)量標(biāo)準(zhǔn)
已經(jīng)有0人回復(fù)
-
求助用微譜數(shù)據(jù)庫(kù)查詢
已經(jīng)有0人回復(fù)
-
藥理學(xué)論文潤(rùn)色/翻譯怎么收費(fèi)?
已經(jīng)有283人回復(fù)
-
計(jì)算化學(xué)與人工智能驅(qū)動(dòng)的MOFs性能預(yù)測(cè)與篩選技術(shù)
已經(jīng)有0人回復(fù)
-
研三實(shí)驗(yàn)求指導(dǎo)
已經(jīng)有0人回復(fù)
-
金屬材料多尺度計(jì)算模擬技術(shù)與應(yīng)用：微觀機(jī)理到宏觀性能的集成工作
已經(jīng)有0人回復(fù)
-
江西科技師范大學(xué)07生物學(xué)和08生物與醫(yī)藥大量調(diào)劑
已經(jīng)有26人回復(fù)
-
【招聘】清北（濟(jì)南）生物科技招聘AI制藥研發(fā)計(jì)算人才
已經(jīng)有15人回復(fù)
-
100701藥學(xué)專業(yè)招調(diào)劑，5個(gè)名額，藥物化學(xué)專業(yè)，主要是天然藥物化學(xué)方向加藥理
已經(jīng)有2人回復(fù)
» 本主題相關(guān)價(jià)值貼推薦，對(duì)您同樣有幫助:
- 求助阿法替尼合成文獻(xiàn)
已經(jīng)有7人回復(fù)
- 【求助】FDA2012年批準(zhǔn)新藥阿西替尼的專利
已經(jīng)有7人回復(fù)
- 達(dá)沙替尼上市時(shí)間？
已經(jīng)有8人回復(fù)
- canertinib卡奈替尼這個(gè)抗腫瘤藥物有沒(méi)有上市？
已經(jīng)有4人回復(fù)
- 求助奧拉西坦國(guó)外上市信息
已經(jīng)有5人回復(fù)
- 【求助】凡德他尼（vandetanib）的上市國(guó)家和時(shí)間及其專利情況
已經(jīng)有3人回復(fù)
- 【求助】請(qǐng)問(wèn)不在美國(guó)上市的藥物可以到什么地方查到藥品研發(fā)信息？以及專利？
已經(jīng)有5人回復(fù)
- 【求助】國(guó)外上市藥品的信息
已經(jīng)有14人回復(fù)
- 【求助】如何查日本上市的藥物信息
已經(jīng)有3人回復(fù)
- 【求助】伊馬替尼的質(zhì)量標(biāo)準(zhǔn)
已經(jīng)有8人回復(fù)
- 【求助】如何尋找多肽上市藥物？有哪些網(wǎng)站？
已經(jīng)有11人回復(fù)
酔欲陶然
木蟲 (正式寫手)
- 應(yīng)助: 7 (幼兒園)
- 金幣: 3995.6
- 散金: 25
- 帖子: 345
- 在線: 263.5小時(shí)
- 蟲號(hào): 855206
- 注冊(cè): 2009-09-23
- 性別: GG
- 專業(yè): 合成藥物化學(xué)
|
Puma Biotechnology, under license from Pfizer (previously Wyeth), is developing neratinib (PB-272; HKI-272), an irreversible pan-HER (Erbb1, ErbB2 and ErbB4) tyrosine kinase inhibitor, for the potential oral treatment of HER2-positive cancers, primarily breast cancer In July 2009, worldwide phase III breast cancer trials were initiated by Wyeth in patients who had received prior trastuzumab-based therapy ; in October 2011, following its acquisition of rights, Puma intended to terminate the ongoing Pfizer-sponsored trials , and the company began its own phase III trial in third-line metastatic breast cancer in June 2013 . In July 2014, Puma planned to file the drug for approval in the extended adjuvant setting for breast cancer in 1H15 . Development in other HER2-positive cancer settings is ongoing. In April 2013, a phase II trial in patients with NSCLC was ongoing . In October 2013, a phase II study in patients with other solid tumors with a HER2 mutation was initiated ; in March 2014, initial data from the trial were expected in 2014 |
5樓2014-08-28 09:04:03
6樓2014-08-28 09:30:07
9樓2014-08-28 14:11:11
2樓2014-08-27 16:55:56
Tina_1988
銅蟲 (初入文壇)
- 應(yīng)助: 0 (幼兒園)
- 金幣: 944.5
- 帖子: 10
- 在線: 37.3小時(shí)
- 蟲號(hào): 2534673
- 注冊(cè): 2013-07-06
- 專業(yè): 有機(jī)合成
3樓2014-08-27 16:58:18
4樓2014-08-28 08:46:35
Tina_1988
銅蟲 (初入文壇)
- 應(yīng)助: 0 (幼兒園)
- 金幣: 944.5
- 帖子: 10
- 在線: 37.3小時(shí)
- 蟲號(hào): 2534673
- 注冊(cè): 2013-07-06
- 專業(yè): 有機(jī)合成
7樓2014-08-28 11:20:00
Tina_1988
銅蟲 (初入文壇)
- 應(yīng)助: 0 (幼兒園)
- 金幣: 944.5
- 帖子: 10
- 在線: 37.3小時(shí)
- 蟲號(hào): 2534673
- 注冊(cè): 2013-07-06
- 專業(yè): 有機(jī)合成
8樓2014-08-28 11:22:08
|
Puma Biotechnology, under license from Pfizer (previously Wyeth), is developing neratinib (PB-272; HKI-272), an irreversible pan-HER (Erbb1, ErbB2 and ErbB4) tyrosine kinase inhibitor, for the potential oral treatment of HER2-positive cancers, primarily breast cancer In July 2009, worldwide phase III breast cancer trials were initiated by Wyeth in patients who had received prior trastuzumab-based therapy ; in October 2011, following its acquisition of rights, Puma intended to terminate the ongoing Pfizer-sponsored trials , and the company began its own phase III trial in third-line metastatic breast cancer in June 2013 . In July 2014, Puma planned to file the drug for approval in the extended adjuvant setting for breast cancer in 1H15 . Development in other HER2-positive cancer settings is ongoing. In April 2013, a phase II trial in patients with NSCLC was ongoing . In October 2013, a phase II study in patients with other solid tumors with a HER2 mutation was initiated ; in March 2014, initial data from the trial were expected in 2014 |
10樓2014-08-28 18:00:06
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 Tina_1988 的主題更新
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 318求調(diào)劑，計(jì)算材料方向 +7 | 吸喵有害笙命 2026-04-01 | 8/400 |
|
|---|---|---|---|---|
|
|
[考研] 296求調(diào)劑 +4 | 汪�。�！ 2026-03-31 | 7/350 |
|
|
|
[考研] 339求調(diào)劑，想調(diào)回江蘇 +7 | 烤麥芽 2026-03-27 | 10/500 |
|
|
|
[考研]
 重慶大學(xué)材料與化工085600，初試370+，求求調(diào)劑建議
+3
|
shzhou_ 2026-04-01 | 3/150 |
|
|
[考研] 320分，材料與化工專業(yè)，求調(diào)劑 +14 | 一定上岸aaa 2026-03-27 | 18/900 |
|
|
|
[考研] 總分343，求生物學(xué)調(diào)劑 +6 | 深刻的凱撒 2026-03-26 | 6/300 |
|
|
|
[碩博家園] 博一被送出聯(lián)培感覺(jué)不適應(yīng)怎么辦 +3 | 全村的狗 2026-03-31 | 3/150 |
|
|
|
[考研] 土木304求調(diào)劑 +5 | 兔突突突， 2026-03-31 | 6/300 |
|
|
|
[考研] 318一志愿吉林大學(xué)生物與醫(yī)藥 求調(diào)劑 +6 | 篤行致遠(yuǎn). 2026-03-28 | 6/300 |
|
|
|
[考研] 材料工程085601數(shù)二英一335求調(diào)劑 +5 | 雙馬尾痞老板2 2026-03-31 | 5/250 |
|
|
|
[考研] 282求調(diào)劑 不挑專業(yè) 求收留 +4 | Yam. 2026-03-30 | 5/250 |
|
|
|
[考研] 求調(diào)劑 +8 | 11ggg 2026-03-30 | 8/400 |
|
|
|
[考研] 269求調(diào)劑 +4 | 我想讀研11 2026-03-31 | 4/200 |
|
|
|
[考研] 一志愿北京化工大學(xué)材料與化工（085600）296求調(diào)劑 +25 | 稻妻小編 2026-03-26 | 25/1250 |
|
|
|
[考研] 求調(diào)劑 +10 | 家佳佳佳佳佳 2026-03-29 | 10/500 |
|
|
|
[考研] 一志愿廈門大學(xué)材料工程專碩354找調(diào)劑�。。� +5 | 貝唄鋇鋇 2026-03-30 | 5/250 |
|
|
|
[考研] 070305高分子化學(xué)與物理 304分求調(diào)劑 +12 | c297914 2026-03-28 | 12/600 |
|
|
|
[考研] 求調(diào)劑 +7 | 爭(zhēng)取九點(diǎn)睡 2026-03-28 | 8/400 |
|
|
|
[考研] 081200-314 +3 | LILIQQ 2026-03-27 | 4/200 |
|
|
|
[考研]
 085602化學(xué)工程求調(diào)劑。
+4
|
平樂(lè)樂(lè)樂(lè) 2026-03-26 | 4/200 |
|